

Title (en)
 NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT-TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT SEQUENCES

Title (de)
 NASAL VERABREICHTE IMPFSTOFFE MIT MULTI-SCREENED NALT-TARGETING UND PHAGOZYTISCHEN POLYPEPTID-TRANSPORTSEQUENZEN

Title (fr)
 VACCINS ADMINISTRÉS PAR VOIE NASALE UTILISANT LE CIBLAGE NALT À DÉTECTION MULTIPLE ET DES SÉQUENCES DE TRANSPORT DE POLYPEPTIDE PHAGOCYTAIRE

Publication
EP 2167110 A4 20120229 (EN)

Application
EP 08756895 A 20080606

Priority
 • AU 2008000811 W 20080606
 • AU 2007202629 A 20070608

Abstract (en)
 [origin: WO2008148164A1] Multiple sequential screening tests have been performed on phage display libraries, and polypeptide sequences have been identified that potentially drive both: (i) intake into mucosal immune cells, including NALT cells in the nose and throat; and, (ii) phagocytic intake and processing by antigen-presenting cells, such as macrophages. Such polypeptide sequences can be used as potent "target and deliver" components in vaccines that can be administered nasally, or to other mucous membranes. Such vaccines can be made very rapidly and in huge quantities, from bacteriophages that will also carry antigenic sequences in their coat proteins, or other immunoactive components. Alternately, such "target and deliver" polypeptides can be incorporated into vaccines derived from eukaryotic viruses or cellular pathogens. Enhancements also are disclosed, such as agents that can activate one or more types of toll-like receptors, to increase immune responses and guide them in desired directions.

IPC 8 full level
A61K 35/76 (2006.01); **A61K 38/02** (2006.01); **A61K 39/12** (2006.01); **A61K 35/13** (2015.01); **A61K 39/00** (2006.01)

CPC (source: EP)
A61K 39/12 (2013.01); **A61P 31/00** (2018.01); **A61K 35/13** (2013.01); **A61K 39/00** (2013.01); **A61K 2039/543** (2013.01); **C12N 2795/14042** (2013.01); **C12N 2795/14045** (2013.01)

Citation (search report)
 • [A] DELMASTRO P ET AL: "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", VACCINE, ELSEVIER LTD, GB, vol. 15, no. 11, 1 August 1997 (1997-08-01), pages 1276 - 1285, XP004086601, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(97)00072-8
 • [A] BUKREYEV ET AL: "Nonsegmented Negative-Strand Viruses as Vaccine Vectors", JOURNAL OF VIROLOGY,, vol. 80, no. 21, 1 November 2006 (2006-11-01), pages 10293 - 10306, XP008109018, DOI: 10.1128/JVI.00919-06
 • See also references of WO 2008148164A1

Designated contracting state (EPC)
 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2008148164 A1 20081211; AU 2007202629 A1 20090108; CA 2727126 A1 20081211; EP 2167110 A1 20100331; EP 2167110 A4 20120229

DOCDB simple family (application)
AU 2008000811 W 20080606; AU 2007202629 A 20070608; CA 2727126 A 20080606; EP 08756895 A 20080606